Date posted: September 18, 2018, 6:00 am
In this episode, we will discuss the advantages and disadvantages of a rate versus rhythm control strategy for atrial fibrillation.
Date posted: August 28, 2018, 6:00 am
In this episode, we discuss the importance of accurately recognizing depressive symptoms in patients with kidney disease and provide review the limited available literature regarding treatment in this population. We then discuss guidelines to determine some of the best treatment options for this unique subgroup of patients.
Date posted: August 7, 2018, 6:00 am
In this episode, we take a closer look at deuteration, specifically involving the medication deutetrabenazine (discussed back in episode 76). We feature a guest contributor from our pharmacy sciences department who assists us as we look at the drug design aspects of this unique molecule and its implications for research moving forward.
Date posted: July 17, 2018, 6:00 am
In this episode, we discuss some ways APPE students not only survive, but excel in the APPE rotations.
Date posted: June 26, 2018, 6:00 am
In this episode, we will review the diagnosis and treatment of heparin-induced thrombocytopenia (HIT).
Date posted: June 5, 2018, 6:00 am
In this episode, we interview Kathleen Lynch, PharmD and Ciantel (Adair) Blyler, PharmD, coauthors of the New England Journal of Medicine article, published in March 2018, investigating the role of pharmacist-led interventions for blood pressure reduction in black barbershops.
Date posted: May 15, 2018, 6:00 am
In this episode, we interview Janeen Winnike, Dean of the Office of Students Affairs at the RFUMS College of Pharmacy, regarding transitions from a student life to a practitioner life. With her previous role as an HR official within a large community pharmacy chain, she offers some “do’s and don’ts” for students transitioning into new practitioners.
Date posted: April 24, 2018, 6:00 am
In this episode, we discuss five clinical pearls about pulmonary embolism ranging from PE diagnosis, classification, and treatment. We specifically examine when and how alteplase is given for PE and its use with concurrent anticoagulation.
Date posted: April 3, 2018, 6:00 am
In this episode, we discuss two new agents (valbenazine and deutetrabenazine) -- the first of their kind to receive FDA approval to manage tardive dyskinesia most commonly associated with antipsychotic use.
Date posted: March 13, 2018, 6:00 am
In the previous episodes, we discussed how we should evaluate a patient’s bleeding and clotting risks as well as looked at recommendation for management for various anticoagulants. In this episode, we will continue the discussion to management of antiplatelets as well as when to resume both antiplatelets and anticoagulants following a procedure.